| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
2 companies
Maha Katabi last filed a Form 4 in May 2025, as Director, 10% Owner at JBIO. The filings on record cover 2 companies. Maha Katabi's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Maha Katabi a strong insider score of 71/100, based on 6 past trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +22.2%.
At the last filing, the largest reported position was 2,793,987 shares of VERA. Net of sales, the VERA filings show accumulation of 54,103 shares.
Maha Katabi has 16 Form 4 filings on record from February 2021 to May 2025, across 2 companies: Director at Vera Therapeutics (VERA), 2021–2025; Director, 10% Owner at Jade Biosciences (JBIO), 2021–2024.
The 26 reported transactions were 15 option or other derivative awards, 6 open-market sales, 3 open-market purchases and 2 conversions.
Counted by filing, the open-market trades come to 3 purchases worth about $18.0M and 1 sale worth about $34.1M.
The largest open-market purchase was 727,272 shares of VERA at an average $11.00 on May 18, 2021, about $8.0M. Twelve months later VERA was up 33%.
The only open-market sale was 834,459 shares of VERA at an average $40.86 on March 25, 2024, about $34.1M. Twelve months later VERA was down 35%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2024 | VERA Vera Therapeutics, Inc. | Director | Sell | 834,459 | $40.86 | $34,099,582.58 | -23.0% | -15.3% | -34.6% | |
| Jan 30, 2024 | VERA Vera Therapeutics, Inc. | Director | Buy | 161,290 | $31.00 | $4,999,990.00 | +4.7% | +19.9% | +9.9% | |
| Jul 2, 2021 | JBIO Jade Biosciences, Inc. | Director, 10% Owner | Buy | 357,142 | $14.00 | $4,999,988.00 | +10.5% | +5.2% | -15.1% | |
| May 18, 2021 | VERA Vera Therapeutics, Inc. | Director, 10% Owner | Buy | 727,272 | $11.00 | $7,999,992.00 | +33.2% | +37.7% | +32.9% |